Any forward-looking statements in this press release speak only as of the date of such statement, and Sensus undertakes no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods.
and other risks described from time to time in Sensus’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
and China, including the concentration of sales to one particular customer in the U.S.
Although Sensus believes that it has a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and actual results of operations, financial condition and liquidity, and the development of the industry in which Sensus operates may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing Sensus’s ability to achieve profitability its ability to obtain and maintain the intellectual property needed to adequately protect its products, and its ability to avoid infringing or otherwise violating the intellectual property rights of third parties the level and availability of government and/or third party payor reimbursement for clinical procedures using Sensus’s products, and the willingness of healthcare providers to purchase its products if the level of reimbursement declines the regulatory requirements applicable to Sensus and its competitors its ability to efficiently manage its manufacturing processes and costs the risks arising from its international operations legislation, regulation, or other governmental action, that affects Sensus’s products, taxes, international trade regulation, or other aspects of its business concentration of its customers in the U.S. This press release includes statements regarding Sensus that are, or may be deemed, ”forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.įorward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, its industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.įor more information, visit Forward-Looking Statements
Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions.